Targeting gene modifications to improve treatments for prostate cancer
Combinational targeting histone and RNA modifications in prostate cancer
This study is exploring new ways to treat advanced prostate cancer by looking at a protein called EZH2 that can affect how cancer cells behave, with the hope of finding better treatment options that work well with what patients are already receiving.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11107533 on NIH RePORTER |
What this research studies
This research investigates new therapeutic strategies for advanced prostate cancer by targeting both genetic and epigenetic modifications. It focuses on the role of the EZH2 protein, which is linked to poor patient outcomes, and how it affects RNA stability and splicing. By understanding these mechanisms, the research aims to develop more effective treatment options that could work alongside existing therapies. Patients may benefit from innovative approaches that could enhance their treatment response and survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have shown resistance to current therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic modifications in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.